Table 4 Prognostic impact of mrTRG in specific pTRG patient subgroups
From: Comparison between MRI and pathology in the assessment of tumour regression grade in rectal cancer
Outcome measure | pTRG/mrTRG subgroup | n Events/ n subjects | 5-year survival (95% CI) | Hazard ratio (95% CI) | P value | Pairwise p value |
|---|---|---|---|---|---|---|
RFS | 1. pTRG 0–1/mrTRG 3–5 | 23/49 | 57.1 (43.2–71.0) | 1.0 | (0.023) | 1 vs 2 |
2. pTRG 0–1/mrTRG 1–2 | 6/16 | 73.3 (50.9–95.6) | 0.64 (0.26–1.60) | 0.34 | 0.391 | |
3. pTRG 2/mrTRG 3–5 | 11/31 | 65.9 (48.7–83.1) | 0.85 (0.41–1.76) | 0.65 | 3 vs 4 | |
4. pTRG 2/mrTRG 1–2 | 6/27 | 76.9 (60.6–93.2) | 0.45 (0.18–1.11) | 0.081 | 0.180 | |
5. pTRG 3–4/mrTRG 3–5 | 3/24 | 87.3 (73.8–100) | 0.25 (0.07–0.84) | 0.025 | 5 vs 6 | |
6. pTRG 3–4/mrTRG 1–2 | 8/44 | 88.5 (78.9–98.1) | 0.30 (0.14–0.68) | 0.004 | 0.974 | |
OS | 1. pTRG 0–1/mrTRG 3–5 | 21/49 | 63.1 (49.6–76.6) | 1.0 | (0.053) | 1 vs 2 |
2. pTRG 0–1/mrTRG 1–2 | 5/16 | 80.0 (59.8–100) | 0.57 (0.21–1.52) | 0.260 | 0.301 | |
3. pTRG 2/mrTRG 3–5 | 10/31 | 68.8 (51.7–85.9) | 0.83 (0.39–1.80) | 0.638 | 3 vs 4 | |
4. pTRG 2/mrTRG 1–2 | 5/27 | 80.6 (65.3–95.9) | 0.45 (0.17–1.20) | 0.110 | 0.220 | |
5. pTRG 3–4/mrTRG 3–5 | 3/24 | 91.7 (78.2–100) | 0.30 (0.09–1.00) | 0.050 | 5 vs 6 | |
6. pTRG 3–4/mrTRG 1–2 | 7/44 | 90.7 (82.1–99.3) | 0.31 (0.013–0.72) | 0.007 | 0.771 |
